The effect of twelve week conjugated linoleic acid (CLA) supplementation on selected markers of atherosclerosis in obese and overweight women.

The effect of twelve week conjugated linoleic acid (CLA) supplementation on selected markers of atherosclerosis in obese and overweight women. - CLA and atherosclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00010469

Enrollment

Registered

2016-05-04

Start date

2014-07-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I70 E66

Interventions

Group 1: Conjugated linoleic acid (CLA)- capsule containing 0.5 g of 80% CLA (50:50 cis-9, trans-11 and trans-10,cis-12 isomers)

dose: 3g per day (per os) for 12 weeks Group 2: Placebo - capsule containing 0.5 g of sunflower oil

dose: 3g per day (per os) for 12 weeks

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Female sex 2. Age greater than 18 years 3. Body mass index (BMI) = 25 kg/m2

Exclusion criteria

Exclusion criteria: 1. A history of chronic systemic disease (with the exception of hypertension). 2. Celiac disease. 3. Type 2 diabetes. 4. Pancreatic and/or liver diseas. 5. Current or recent (within the preceding month) treatment with CLA or agents interfering with fat digestion and/or absorption (chitosan, orlistat, green tea) 6. Pregnancy

Design outcomes

Primary

Measure	Time frame
concentration of high-sensitive C-reactive protein (hs-CRP) at the study begin and after nutritional intervention	—

Secondary

Measure	Time frame
concentration of assymetric dimethylarginine (ADMA) at the study begin and after nutritional intervention	—

Countries

Poland

Contacts

Public ContactJaroslaw Walkowiak

Department of Pediatric Gastroenterology and Metabolic DiseasesPoznan University of Medical Sciences

jarwalk@ump.edu.pl+48 618491432

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026